Capsaicin: The Near-Perfect TRPV1 Agonist 

The objective of this webinar is to review the potential, promise and now fulfillment of non-opioid, TRPV1 agonists (e.g., capsaicin) as pharmacological interventions for the treatment of pain of peripheral origin. This session will review TRPV1 biology, the previously unfulfilled promise and limitations of TRPV1 therapeutics for the management of nociceptor mediated pain, and their recent clinical renaissance as effective, durable, and safe therapeutics for the management of osteoarthritic, neuropathic, and post-surgical pain.

Learning Objectives:

  • Review the historical use of capsaicin up to FDA’s acknowledgement of the benefit of topical capsaicin for the treatment of pain
  • To present findings from recent RCTs that evaluated and confirmed the promise of higher strength capsaicin products as treatments for osteoarthritic, neuropathic, and post-surgical pain
  • Review the validation and limitations of OTC-strength capsaicin for the management of pain from randomized clinical trials (RCTs)
  • To propose future opportunities for the investigation of topical capsaicin for the treatment of osteoarthritis and neuropathic pain
  • Review the biological studies that underpinned the pharmaceutical industry efforts to utilize TRPV1 as a rational drug design target


Tim Warneke, MS, Vice President Clinical Operations, Propella Therapeutics, Inc.

Tim Warneke has more than 30 years of pharmaceutical development experience in clinical operations. These experiences range across large (Ciba-Geigy and Abbott Laboratories) to mid-size (King Pharmaceuticals) pharmaceutical companies and now Propella Therapeutics (formally Vizuri Heath Sciences).  

Tim has leveraged his expert knowledge of the Code of Federal Regulations and Good Clinical Practice to provide operational excellence in support of numerous INDs and NDAs throughout his career.  Prior to Propella Therapeutics, Tim lead the clinical development team at BioDelivery Sciences International that obtained FDA approval of Belbuca® for the management of chronic pain requiring opioids.

Date: February 9, 2021

Time: 1:00 pm Central Standard

Brought to you by Arrowhead Publishers, the organizers of the:

Registrant agrees to receive all e-mails specific to the webinar they are registering for, including a post-webinar follow-up from the sponsor of this webinar.